Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Europe entities : Nls pharmaceutics ltd save search
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
Published: 2024-03-14 (Crawled : 12:30) - biospace.com/
NLSP | $0.1348 3.77% 3.64% 320K
|
|
| O: 2.52%
H: 0.0%
C: -4.31%
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance
Published: 2024-03-11 (Crawled : 12:00) - biospace.com/
NLSP | $0.1348 3.77% 3.64% 320K
|
|
| O: 4.99%
H: 11.89%
C: 3.79%
nasdaq
CORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
Published: 2023-06-19 (Crawled : 13:00) - biospace.com/
NLSP | $0.1348 3.77% 3.64% 320K
|
| Email alert
Add to watchlist
conference group
NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol
Published: 2023-06-14 (Crawled : 23:00) - biospace.com/
NLSP | $0.1348 3.77% 3.64% 320K
|
|
| O: 1.04%
H: 5.15%
C: -5.67%
cyp450 positive in vitro
NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer
Published: 2023-05-08 (Crawled : 13:00) - biospace.com/
NLSP | $0.1348 3.77% 3.64% 320K
|
|
| O: -2.17%
H: 2.22%
C: -0.74%
financial
NLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023
Published: 2023-05-04 (Crawled : 14:00) - biospace.com/
NLSP | $0.1348 3.77% 3.64% 320K
|
|
| O: -2.24%
H: 0.0%
C: -3.01%
preclinical
NLS Pharmaceutics Presents Latest Preclinical Pipeline Data at American Society of Clinical Psychopharmacology
Published: 2023-04-25 (Crawled : 13:20) - biospace.com/
NLSP | $0.1348 3.77% 3.64% 320K
|
|
| O: 1.37%
H: 0.01%
C: -1.35%
pipeline preclinical
NLS Pharmaceutics to Present at the 35th Annual Roth Conference
Published: 2023-03-01 (Crawled : 16:00) - biospace.com/
NLSP | $0.1348 3.77% 3.64% 320K
|
|
| O: -2.8%
H: 5.04%
C: 0.72%
conference
NLS Pharmaceutics Regains Compliance with Nasdaq Stockholders' Equity Requirement
Published: 2023-01-25 (Crawled : 14:00) - biospace.com/
NLSP | $0.1348 3.77% 3.64% 320K
|
|
| O: 0.0%
H: 6.9%
C: -1.38%
nasdaq
NLS Pharmaceutics Announces New In-Vitro Data Reconfirming Quilience's(R) (Mazindol ER) Unique Dual Mechanism of Action Involving Significant Orexin-2 Receptor Activity
Published: 2023-01-23 (Crawled : 14:00) - biospace.com/
NLSP | $0.1348 3.77% 3.64% 320K
|
|
| O: -0.7%
H: 12.67%
C: 4.38%
in-vitro unique in vitro
NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement
Published: 2023-01-12 (Crawled : 14:20) - biospace.com/
NLSP | $0.1348 3.77% 3.64% 320K
|
|
| O: 0.0%
H: 0.0%
C: -2.75%
nasdaq
NLS Pharmaceutics to Participate in Upcoming Investor Conferences - January 11, 2023
Published: 2023-01-11 (Crawled : 14:00) - biospace.com/
NLSP | $0.1348 3.77% 3.64% 320K
|
|
| O: -2.94%
H: 12.12%
C: 10.3%
NLS Pharmaceutics Announces Technology Patent Grant Covering Mazindol for Treatment of Attention Deficit Hyperactivity Disorder and Rare Sleep Disorders in Hong Kong
Published: 2023-01-10 (Crawled : 16:00) - biospace.com/
NLSP | $0.1348 3.77% 3.64% 320K
|
|
| O: 2.58%
H: 8.18%
C: 6.92%
treatment rare patent grant technology
NLS Pharmaceutics Announces Israeli Patent Grant Covering Mazindol for Treatment of Attention Deficit Hyperactivity Disorder and Other Sleep Disorders Through 2037
Published: 2022-12-20 (Crawled : 15:00) - biospace.com/
NLSP | $0.1348 3.77% 3.64% 320K
|
|
| O: 0.0%
H: 0.0%
C: 0.0%
treatment patent grant
NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification - December 7, 2022
Published: 2022-12-07 (Crawled : 14:00) - biospace.com/
NLSP | $0.1348 3.77% 3.64% 320K
|
|
| O: 12.07%
H: 0.0%
C: -8.87%
nasdaq
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
Published: 2022-10-05 (Crawled : 23:00) - biospace.com/
NLSP | $0.1348 3.77% 3.64% 320K
|
|
| O: -2.03%
H: 9.24%
C: 7.42%
NLS Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience(R) for the Treatment of Narcolepsy
Published: 2022-06-02 (Crawled : 14:00) - biospace.com/
NLSP | $0.1348 3.77% 3.64% 320K
|
|
| O: -1.34%
H: 4.35%
C: -0.22%
treatment narcolepsy trial phase 2b
NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment
Published: 2021-09-28 (Crawled : 13:00) - biospace.com/
NLSP | $0.1348 3.77% 3.64% 320K
|
|
| O: -1.96%
H: 3.6%
C: -1.2%
distribution
NLS Pharmaceutics Announces FDA Acceptance of IND Application to Initiate Clinical Trials with Quilience(R) (mazindol ER) to Treat Narcolepsy
Published: 2021-07-15 (Crawled : 13:00) - biospace.com/
NLSP | $0.1348 3.77% 3.64% 320K
|
|
| O: 12.62%
H: 9.73%
C: -7.37%
fda fda acceptance clinical trials narcolepsy trial application
NLS Pharmaceutics Announces Patent Issuance in Europe for its Mazindol Controlled-Release Formulation (Mazindol CR)
Published: 2021-05-05 (Crawled : 14:15) - biospace.com/
NLSP | $0.1348 3.77% 3.64% 320K
|
|
| O: 0.0%
H: 1.19%
C: -3.87%
europe patent
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 870K
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.